MeiraGTx Holdings Plc (MGTX)

MeiraGTx's stock has fluctuated between $9.73 and $4.55 over the past six months, trading around $7.20 to $7.56 in early February 2026. Key events include an exclusive license agreement with ZipBio in February 2026, a "Moderate Buy" consensus rating from analysts in January 2026, insider selling, and an agreement to repurchase shares from Perceptive. The company presented at the Evercore 8th Annual Healthcare Conference in December 2025. In November 2025, MeiraGTx reported its Third Quarter 2025 financial results and announced a collaboration with Eli Lilly and Company. MeiraGTx announced posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress in October 2025. MeiraGTx reported its Second Quarter 2025 financial results in August 2025.

Information regarding specific demand seasonality for MeiraGTx Holdings Plc's products and services is not readily available. Demand for its products is primarily driven by clinical trial progress, regulatory approvals, and eventual commercialization, rather than typical consumer seasonality.

MeiraGTx Holdings Plc is a clinical-stage genetic medicines company focused on developing treatments for serious diseases within the biotechnology sector. It is vertically integrated with end-to-end capabilities in vector engineering, viral vector production, manufacturing, and quality control. The company's pipeline targets ocular diseases, neurodegenerative diseases, xerostomia, and other platforms, including cell therapies for oncology, autoimmune diseases, and long-term intractable pain.

MeiraGTx Holdings Plc is based in New York, United States, and has established comprehensive manufacturing capabilities globally. It operates five facilities, including two licensed for GMP viral vector production and a GMP Quality Control facility, located across the United Kingdom and the United States.

MeiraGTx generally holds a "Moderate Buy" consensus rating from analysts, reflecting confidence in its future potential, bolstered by strategic collaborations with major pharmaceutical companies like Eli Lilly and Hologen AI. However, financial challenges, including a significant drop in revenue growth, negative earnings per share, and a concerning return on equity, could impact its reputation among some investors.

MeiraGTx Holdings Plc has 207 institutional owners holding 67,343,026 shares, including Perceptive Advisors Llc, Sanofi, and Johnson & Johnson Innovation - JJDC, Inc. Individual owners include the CEO, President & Director, Alexandria Forbes, and other officers who have engaged in stock transactions.